Newspaper Page Text
Please read tills summary caretully and then ask your doctor about CRESTOR Ho advertisement can provide all the information needed to determine it a drag is right for you.
Tbit advertisement dots not take Iht plate ol caratal discussions with your doctor. Only your doctor has the training to weigh the risks and benelits ol a prescription drag
BtHF SUMMARY: For ful Prescribing Information, see package insert.
INDICATIONS AND USAG£ CRESTOR is indicated 1 as an adjunct to diet to
reduce elevated totat-C. LOL C. Apoß iwHOt C. and TG levels and to increase HOl-C m
Wtients wth primary tryperchotetefotemta (hetentamrtiali and mixed tfystiprdemia
(Fredickson Type Ha and lib); 2 as an adjunct to d*t for the treatment ot patents v.rth
elevated serum TG levels (Fredrickson Type IV) 3 to reduce LOl-C. totat-C. and Apoß in
patients wth homozygous familial hyperchotesterotenna as an adjunct to other
lipid-iottenng treatments (If.. LOL apheresis) or it such treatments are unavailable
CONTRAINDICATIONS CRESTOR is contraindicated m patients vrib a known
bypmmKeily to any component of this product Rosuvastatin is conframdcated in
patients with active liver disease or with unexptamed persistent elevations of serum
transaminases (see WARNINGS Liver Enzymes* Pregnancy and lactation
Afheroscferosis is a chrome process and discontinuation of fipMkraamg drugs during
pregnancy should have kttle impact on the outcome ol long term therapy ol primary
hypercholesterolemia Cholesterol and other products of cholesterol biosynthesis are
essential components tor fetal development (metudmg synthesis of steroids and cell
membranes) Shic« HMG-CoA reductase inhibitors decrease cholesterol synthesis and
possibly the synthesis ot other biologically active substances derived from cholesterol,
they may cause fetal harm when administered to pregnant women Therefore. HMG-CoA
reductase mtMtxfors are contramdicafed during pregnancy and m nursing mothers
ROSUVASTATIN SHOULD BE AOMMSTEREO TO WOMEN OF CHILDBEARING AGE ONLY
WHEN SUCH PATIENTS ARE HIGHLY UNLIKELY TO CONCEIVE ANO HAVE BEEN
RJFORMEO OF THE POTENTIAL HAZAROS. It the patient becomes pregnant while taking
this drug, therapy should be discontinued immediitely and the patient apprised of the
potential hazard to the fetus.
WARNINGS liver Enzymes HMGCoA reductase inhibitors like some other Irpid
towenng therapies, have been associated with biochemical abnormalities of hver function.
The incidence of persistent elevations (>3 times the upper limit of norma) (ULNj occur
ring on 2 or more consecutive occasions) m serum transaminases m fixed dose studes
was 0.4. 0. 0. and 0.1% m patients who received rosuvastatin 5. 10. 20. and 40 mg.
respectively. In most cases, the elevations were transient and resolved or improved on
continued therapy or after a brief interruption m therapy There were two cases ol jaundice
for winch a relationship to rosuvastatin therapy could not be determined which resolved
after discontinuation of therapy There were no cases of liver failure or irreversible liver
disease m these trie's R is recommended that liver function tests be performed before
and at 12 weeks Moving both the Miration ft therapy and any elevation of dose, and
pertodkiNy (e g., semianmiaffy) thereafter. Liver enzyme changes generally occur in
the first 3 months ol treatment with rosuvastatm Patients who develop increased
transaminase levels should Ik monitored until the abnormalities have resolved Should an
increase in ALT or AST of >3 fates UIN persrst reduction of dose or withdrawal of
rosuvastatm is recommended. Rosuvastatm should be used with caution m patients who
consume substantial quantities of alcohol and'or have a history of liver disease isee CLIN
ICAL PHARMACOLOGY Special Populations Hepatic Insufficiency). Active liver disease or
unexplained persistent transaminase elevations are contraindications to the use of rosuva
statin isee CONTRAINOCATIONSi Myopathy/Rhobdomyolysis Rare cases ol
rhahdomyolysis with acute renal failure secondary to ayoglobiMria have been
reported with rosuvastatm and will other drugs to this class. Uncomplicated Myalgia
his been reported m rosuvastotm-treafed patients isee ADVERSE REACTIONS) Creatine
kmase (CK) elevations i>lo times upper limit of norma!) occurred m 02% to 0,4°. of
patients Wong rosuvastatm at doses up to 40 mg m dimeal studies. Treatment-related
myopathy, defined as muscle aches or muscle weakness n conjunction with increases in
CK values >lO times upper limit of norma) was repotted m up to 01% o! patients taking
rosuvastatm doses of up to 40 mg m chnicat studies In dimeal trials the incidence of
myopathy and rtiaMomyofyss increased at doses of rosuvastafm above the recom
mended dosage range (5 to 40 mg) In postmarking expenence effects on skeleial
muscle e.g. uncompltated myalgia myopathy and. rarely rhahdomyolysis have been
reported in pabents treated with HMG-CoA reductase inhibitors mduding rosuvastatm As
with other HMG CoA reductase mhjktors. reports of rfvabdomyotysrs with rosuvastatm
are rare, but higher at the behest marketed dose (40 mgi Factors that may predispose
patients to myopathy with HMG-CoA reductase inhibitors include advanced age i>6s
years), hypothyrouhsm. and renal insufficiency. Consequently 1. Rosuvasfatm should be
prescribed with caution m patients with predisoosmg tactors lor myopathy, such as renal
impairment (see DOSAGE AND ADMINISTRATION), advanced age and inadequately
treated hypothyroidism 2 Patients should be advised to promptly report unexp’amed
muscle pam, tenderness, or weakness, particularly if accompanied by malaise or fever
Rosuvastatm therapy should be discontinued if markedly elevated CK levels occur or
myopathy is toagnosed or suspected 3. The 40 mg dose ot rosuvastatm is reserved only
for those patients who have not achieved their IDL-C goal utilizing the 20 mg dose of
rosuvastatm once daily isee OOSAGE AND ADMINISTRATION! 4 The risk of myopathy
during treatment vnth rosuvastatm may be increased with concurrent administration of
other bpid-toivering therapes or cyclosporine (see CLINICAL PHARMACOLOGY Drug
Interactions PRECAUTIONS Drug Interactions and OOSAGE AND ADMINISTRATION)
The benefit ot huther alterations to lipid levels by Ibe combined use of rosevastalm
with literates or macm should be carefully weighed against the potential risks ot Ibis
combination. Combination therapy with rosuvastatm and gemfibrozil should generally
be avoided. (See OOSAGE ANO ADMINISTRATION and PRECAUTIONS. Drug
Meractions) 5 The risk ot myopathy during treatment with rosovastalin may be
increased m circumstances which increase rosovaslalin drug levels (see CLINICAL
PHARMACOLOGY. Special Populations. Race and Renal Insufficiency, and PRECAU
TIONS. General). 6 Rosuvastatm therapy should also be temporarily wilhheM in any
patient with an acute, senous condition suggestive it myopathy or predisposing to the
developHKnt of renal failure secondary to rhahdomyolysis (e.g.. sepsis, hypotension,
dehydration major swgery. trauma sovere metabolic, endocrine, and eiectrotyte
disorders or eeconiroiled seizures).
PRECAUTIONS General Before instituting therapy with rosirvastatin an attempi
should be made to control hypercholesterolemia with appropriate diet and exercise,
weight reduction m obese patients, and treatment of underlying medical problems (see
INDICATIONS ANO USAGE). Administration of rosuvasfatm 20 mg to patients with severe
renal impairment
concentrations ol rosuvastatm compared with healthy volunteers (see WARNINGS.
Myopathy'Rhibdomyoiysrs and DOSAGE AND ADMINISTRATION! The result of a large
pharmacokmrtic study conducted m the US demonstrated an approximate 2-foto elevation
m median exposure in Asian subjects (havmg either Filipino. Chinese. Japanese Korean.
Vietnamese or Asian-Indian origin) compared with a Caucasian control group This
increase should be considered when making rosuvastatm dosing decemns for Asi3n
patients (See WARNINGS. Myopathy Rhabdomyolysis CLINICAL PHARMACOLOGY
Special Populations Race, and OOSAGE ANO ADMINISTRATION i Information for
Potranh Patents should be advsed to report promptly unexplained muse'e pain, tender
ness. or weakness, particularly if accompaned by malaise or fiver. When taking rosuva
statin with an aluminum and magnesium hydroxide combination antac d the antacid
should be taken at least 2 hours after rosuvastatm administration isee CLINICAL PHAR
MACOIOGY. Drug Interactions) Laboratory Tests in the rosuvastatm clinical trial
program, dipstick-positive proteinuria and microscopic hematuria were observed among
rosuvastatm-treated patients predominantly in patients dosed above the recommended
dose range fie.. 80 mg). However, this fading was more frequent in patients faking
rosuvastatm 40 mg. when compared to tower doses ot rosuvastatm or comparator statins,
though it was generally transient and was not associated with worsening renal function
Although the ckmcaf significance of this fading is unknown, a dose reduction should be
considered for patents on rosuvastatm 40 mg therapy with unexplained persistent
proteinuria during routine urinalysis testing Drug Interactions Cydospunwe: When
rosuvastatm 10 mg was coadministered with cyclosporine m cardiac transput patents
rosuvastatm mean and mean AUC were increased 11-Wd and 7-fold, respectively
compared with healthy volunteers These increases are considered to be cUmcalfy signifi
cant and require special cons Mon m the dosing ol rosuvastatm to patients taking
conconnant cyclosporine (see WARNINGS. Myopathy Rhabdomyotysis. and OOSAGE
ANO ADMINISTRATION) Warfarin: Coadministration of rosuvastatm to patients on stable
warfarin therapy resulted m clinically significant nses in INR (>4. baseline 2-3). In
patients taking coumarm anticoagu'ants and rosuvastatm concomitantly. INR should be
determined before starting rosuvastatm and frequently enough during earty therapy to
ensure that no significant alteration ol INR occurs Once a stable INR time has been docu
mented. INR can be monitored at the interval usually recommended for patients on
coumarm anticoagulants if the dose of rosuvastatm is changed, the same procedure
should be repeated Rosuvastatm therapy has not been associated with Weeding or with
changes in INR in patients not taking anticoagulants Gimtibrazil; Coadnumstration of a
single rosuvastatm dose to heathy volunteers on gemfibrozil (600 mg twice darfy)
resulted in a 22- and 1.9-tod respective),' increase in mean Crra* and mean AUC of
rosuvasfatm (see DOSAGE ANO ADMINISTRATION) Endocrine Function Although
dimeal studies have shown that rosuvastatm alone does not reduce basal plasma cortisol
concentration or impair adrenal reserve, caution should be exercised it any HMG-CoA
reductase inhibitor or other agent used to lower cholesterol levels is administered
concomitantiy with drugs that may decrease the levels or activity of endogenous steroid
hormones such as ketoconazo'e. spironolactone and ometidine. CNS Toxicity CNS
vascular lesions, characterized by perwascuiar hemorrhages, edema and mononuclear
ceil infiltration ol perivascular spaces, have been observed m dogs treated with several
other members ot this drug class A chemical! 1 / svmiar drug in this class produced dose
dependent optic nerve degeneration (Walenan degeneration of retinogen-culate fibers) in
degs at a dose that produced plasma drug levels about 30 times higher than the mean
drug level m humans taking the highest recommended dose Edema, hemorrhage and
partial necrosis m the mtersfamm of the choroid plexus was observed m a female deg
sacrificed moribund at day 24 at 90 mgkgday by oral garage (systemic exposures 100
times the human exposure at 40 mgday based on AUC comparisons) Corneal opacify
was seen m dogs treated for 52 weeks at 6 mg kg day by oral gavage (systemic exposures
20 times the human exposure at 40 mgtoay based on AUC comparisons) Cataracts were
seen m dogs treated for 12 weeks try oral gavage at 30 mgkg/day (systemic exposures 60
OS
CRESTOR
rosuvastatin calcium
times the human exposure at 40 mg day based on AUC comparisons). Retinal dysplasia
and retinal toss were seen in dogs treated for 4 weeks by oral gavage at 90 mg kg day
(systemic exposures 100 times the human exposure at 40 mg day based on AUCi Doses
<3O mgkgday (systemic exposures <6O times the human exposure at 40 mg day based
on AUC comparisons) foWoning treatment up to one year, did not reveal retinal findings
Corcinogenesis, Mutagenesis, Impairment of Fertility In a 104-week
carcinogenicity study m rats at dose levels of 2.20.60 or 80 mgkg day by oral gavage
the incidence of uterine stromal potyps was sigmlicantty increased in females at
80 mg kg day at systemic exposure 20 times the human exposure at 40 mg day based on
AUC increased incidence of polyps was not seen at tower doses in a 107-week carono-
Qenirty study in mice grven 10. 60 200 mgkgday try oral gavage an increased
incidence of hepatocellular adenoma carcinoma was observed a? 200 mgkgday at
systemic exposures 20 times human exposure at 40 mg day based on AUC An increased
incidence of hepatoceEu>af tumors was not seen at loner doses Rosuvastatm was not
mutagenic or ciastogemc with or without metabolic activation in the Ames test with
Salmonella fyphmmmand Eschenctua cob. the mouse lymphoma assay, and the chro
mosomal aberration assay in Chinese hamster lung ceds Rosuvastatm was negative in the
in wro mouse micronucieus test. In rat tertdrty studies with oral gavage doses ot 5.15.
50 mg kg day males were treated for 9 weeks prior to and throughout mating and females
were treated 2 weeks prior to mating and throughout mating until gestation day 7 No
adverse effect on fertility was observed at 50 mg'kgday (systemic exposures up to 10
times human exccsure at 40 mgday based on AUC compansonsi In testicles of dogs
healed with rosuvastatm at 30 mg kgday for one momh spermaiidic giant ceils were
seen Spermatic gam cells were observed m monkeys atter 6-month treatment at
30 mg kg day in addition to vacuolation of seminiferous tubular epithelium Exposures in
the dog were 20 times and m the monkey 10 times human exposure at 40 mg day based
on body surface area comparisons Snfaar fad-rgs have been seen with other drugs m
this class Pregnoncy Pregnancy Category JSee CONTRAINDICATIONS Rosuvastatm
may cause fetal harm when administered to a pregnant woman Rosuvastatin is
contraindicated in women who are or may become pregnant Safety m pregnant women
has not been established There are no adequate and well-controlled studies of rosuva
statin m pregnant women Rosuvastatm crosses the placenta and is found in fetai tissue
and ammotic fluid at 3% and 20%. respectively, of the maternal plasma concentration
following a single 25 mg kg oral gavage dose on gestation day 16 m rats. A higher fetal
tissue distribution i 25% maternal plasma concentration) was observed in rabbits alter a
single oral gavage dose of 1 mg kg on gestation day 18 If this drug is administered to a
woman with reproductive potential, the patient should be apprised of the potential hazard
to a fetus in female rats given oral gavage doses of S 15.50 mg kg day rosuvastatm
before mating and continuing through day 7 postcclus results m decreased feta) body
weight (female pupsi and de'ayed ossification at the high dose (systemic exposures 10
times human exposure at 40 mg day based on AUC comparisons) In pregnant rats given
oral gavage doses of 2.20 50 mg kg day from gestation day 7 through lactation da-/ 2f
(weaning), decreased pup survival occurred in groups given 50 mg kg day. systemic
exposures >l2 times human exposure at 40 mg day based on body surface area compar
isons In pregnant rabbits given oral gavage doses of 0.3.1.3 mg kg day from gestation
dry 6 to lactation day 18 (weaning), exposures equrvaient to human exposure at
40 mgday based on body surface area comparisons, decreased fetal viability
and maternal mortality was observed. Rosuvastatin was not teratogenic in rats at
<25 mg kg day or in rabbits <3 mg kg day (systemic exposures equrvaient to human
exposure a( 40 mgday based on AUC or body surface comparison, respectively)
Nursing Mothers It is not known whether rosuvastatm is excreted in human milk
Studies in lactatmg rats have demonstrated that rosuvastatin is secreted into breast milk
at levels 3 times higher than that obtained m the plasma Mowing oral gavage dosmg
Because many drugs are excreted in human milk and because of the potential tor senous
adverse reactions in nursing infants horn rosuvastatin. a decision should be made
whether to discontinue nursing or administration of rosuvastatin taking into account the
importance of the drug to the lactatmg woman. Pediatric Use The safety and effec
tiveness m oediainc patients have not been established Treatment experience with
rosuvastatin in a ped atnc population is titrated to 8 patents with homor/gous f H None
of these patients teas below 8 years of age Geriatric Use Of the 10,275 patients in
dimeal studies with rosuvastatin 3.159 (31%| were 65 years and older and 698 16.8%)
were 75 years and older The overall frequency of adverse events and hypes of adverse
events were sum!ar m patients above and Mow 65 years of age (See WARNINGS.
Myopathy Rhabdomyotysis i The efficacy ot rosuvastatm m the geriatric population i >65
years of agei was comparabte to the efficacy observed in the non-eiderly
ADVERSE REACTIONS Rosuvasfatm s generally well tolerated Adverse reactions
have usually been mitd and transient In cfaical studies ot 10.275 pabents. 37% were
discontinued due to adverse experiences attributable to rosuvastatm. The most frequent
adverse events thought to be related to rosuvastatm were myalgia constipation, asthenia
abdominal pam and nausea Clinical Adverse Experiences Adverse experiences
regardless of causality assessment, reported in >2% ot patients in placebo-controlled
clinical studies ot rosuvastatin are shown in Table t; discontinuations due to adverse
events in these studies of up to 12 weeks duration occurred m 3% ol patients on rosuva
statin and 5% on placebo.
Table 1. Adverse Emit in Plitek-Controlled Studies
Rosuvastatm Placebo
Adverse event N=744 N»382
Pharyngitis 90 7"§
Headache 55 50
Diarrhea 34 29
Oyspepsia 3.4 3.1
Nausea 3.4 3.1
Myalgia 2 8 1.3
Asthena 2.7 26
Back pam 26 2.4
Flu syndrome 2.3 18
Urinary tract infection 23 1.6
Rhinitis 22 2.1
Sinusitis 20 18
in addition, the toitow-mg adverse events were reported, regardless of causality assess
ment. m >!% of 10.275 patients treated with rosuvastatm in efimeaf studies The events
m dates occurred in >2% of these patients Body as a Whole: Abdominal pam. acci
dental mpjry. chest pam mfedton. pam. pelvic pam. and neck pain Caidwvascular
System: Hypertension angina pectoris, vasodilatation, and palpitation Digestive
System: Constipation gastroenteritis, vomitng. flatulence periodontal abscess, and
gastritis Endocrine: Diabetes melktuk Hemic aRd Lymphatic System: Anem-a and
eccbymosis. Metabolic and Nutritional Disorders: Peripheral edema Musculoskeletal
System: Arthritis, arthralgia and pathological fracture Nervous System: Dimness,
msomma. hypertonia paresthesia, depression anxiety, vertigo and neuralgia
Respiratory System: Bronchitis cough increased dyspnea, pneumonia and asthma
Skin and Appendages: Rash and pruritus Labnratary Abnormalities In the rosuvastatm
clinical trial program, dipstick-positr.e protemuna and microscopic hematuria were
observed among rosuvastatm-treated patients, predominantly m patients dosed above the
recommended dose range (i.e. 80 mg). However, this fading was more frequent in
patients taking rosuvastatin 40 mg. when compared to lower doses of rosuvastatm or
comparator statins, though it was generally transient and was not associated with wors
ening renal function. (See PRECAUTIONS. Laboratory Tests) Other abnormal laboratory
values reported were elevated creatinine phosphokinase. transammases. hyperglycemia,
glutamyl transpeptidase alkalme phosphatase, bilirubin. and thyroid function abnormali
ties Other adverse events reported less frequently than 1% in the rosuvastatin
clinical study program, regardless of causality assessment, me Wed arrhythmia,
hepatitis, hypersensitivity reactions fie. lace edema, thrombocytopenia, leukopenia.
vesiculobußous rash, urticaria, and angioedemaj. kidney failure syncope myasthenia,
myositis, pancreatitis, photosensitivity reaction myopathy, and rhabdomyolysis
Poshnorketing Experience In addition to the events reported above, as with other
drugs m this class the following event has been reported during post-marketing experi
ence with CRESTOR. regardless of causakty assessment wry rare cases ot jaundice
OVERDOSAGE There is no specific treatment in the event of overdose in the event
of overdose the patient should be treated symptomatically and supportive measures
instituted as required Hemodialysis does not significantly enhance clearance of
rosuvastatm
DOSAGE AND ADMINISTRATION Tte patient should be placed on a standard
cholesterol-lowering diet before receiving CRESTOR and should continue on this diet
durmg treatment CRESTOR can be administered as a single dose at any time of day with
or without ?cod Hypercholesterolemia (Heterozygous Fomilid and
NonfamilioO and Mixed Dyslipidemia (Fredrickson Type lla and lib)
The dose range for CRESTOR'S 5t040 mg once dad; Therapy with CRESTOR should be
individualized according to goal of therapy and response The usual recommended
starting dose of CRESTOR is 10 mg once daily. However, initiation ot therapy with 5 mg
once daily should be considered for patients requiring less aggressive LOL-C reductions
who have predisposing tactors for myopathy, and as noted below tor special populations
such as patients taking cyclosporine. Asian patients, and patients with severe renal insuf
ficiency isee CLINICAL PHARMACOLOGY Race and Renal Insufficiency and Drug
Interactions For patients with marked hypercholesterolemia (IDL-C >l9O mgtfl) and
aggressive fipid targets a 20-mg starting dose may be considered After initiation and 'or
upon titration ot CRESTOR hpid levels should be analyzed within 2 to 4 weeks and dosage
adjusted according!/ The 40 mg dose ot CRESTOR is reserved only tor those patieirts
who have not achieved their LDI-C goal utilizing the 20 mg dose of CRESTOR once
daily (see WARNINGS. Myopalhy/Rhabdomyotysis). When initiating statin therapy or
switching Irom another statin therapy, the appropriate CRESTOR starting dose should
first be utilized, and only then titrated according to the patient $ individualized goat oi
therapy. Homozygous Familial Hypercholesterolemia 'he recommended
starting dose of CRESTOR is 20 mg once daily in patients with homozygous FH The
maximum recommended daily dose is 40 mg CRESTOR should be used m these patients
as an adjunct to other lipid-lowering treatments le g . LDL apheresis) or it such treatments
are unavailable Response to therapy should be estimated from pre-apherests LOL-C
levels Dosage in Asian Patients Initiation of CRESTOR therapy wdh 5 mg once
daily should be considered for Avan patients The potential lor increased systemic expo
sures relative to Caucasians is relevant when cons-deung escalation of dose in cases
where hypercholesterolemia is not adequate)/ contro'led at doses ot 5.10 or 20 mg once
daily (See WARNINGS. Myopathy Rhabdomyotysis. CLINICAL PHARMACOLOGY. Spec-al
Populations. Race and PRECAUTIONS. General) Dosage in Patients Taking
Cyclosporine In patients taking cyclosporine, therapy should be limited to CRESTOR
5 mg once daily (see WARNINGS. Myopathy Rhabdomyoiys>s. and PRECAUTIONS Drug
Interactions! Concomitant Lipid-Lowering Therapy The effect of CRESTOR on
LDL-C and totat-C may be enhanced 1 when used m combination with a bile acid binding
resin II CRESTOR -s used m combination with gemfibrozil, the dose of CRESTOR should
be limited to 10 mg once daily (see WARNINGS Myopathy Rhabdomyolysts. and
PRECAUTIONS Drug Interactions) Dosage in Patients With Renal
Insufficiency No modification of dosage is necessary for patients with mid to
moderate renal insufficiency For patients wits! severe renal impairment
<Cl tr <3O mL mm'l73 m) not on hemcdalyvs dosmg of CRESTOR should be started
at 5 mg once daily and not to exceed 10 mg once daily (see PRECAUTIONS. General, and
CLINICAL PHARMACOLOGY. Special Popu’afions. Rena! Insufficiency).
NOTE: This summary provides important information about CRESTOR For more infor
mation. please ask your doctor or health cite professional about the foH Prescribing
Information and discuss it with them
Rxonly
CRESTOR is a trademark of the AstraZeneca group of companies Z AstraZeneca 2005
Licensed from SHIONOGI &CO LTO. Osaka Japan
Manufactured tor AstraZeneca Pharmaceuticals LP
Wilmington 0E19850
By IPR Pharmaceuticals. Inc
Carolina PR 00984
PCC 630101 A
30043-00 31028-00 a a -y
Rev o3/os 230799 AstraZeneca &
(Continued from page 3)
Faxworthy has parlayed his Southern roots into
a 20-year career that shows no signs of slewing . He
has stand-up tour dates lined up in comedy clubs
and other venues throughout 2(X)6, hosts a weekly
country countdown radio show and is working on a
third Blue Collar Comedy Tour movie.
He’s also planning to host the upcoming CMT
Music Awards, which will air live April 10. He
hosted the show in 2005 and it received record rat
ings for the network.
But even with one foot in die show-business
fast lane, Fbxworthy says lie has purposely made
his life as normal as it can be. “I got invited to host
a dinner at the White House once, but I coukln’t
go because it was the same night as my daughter's,
play at school,” he says. "Twenty years from now, the
president won’t remember if 1 came to the White
House. But my daughter will remember if I wasn’t
at her play.”
Foxworthy’s career evolved out of a friendly
good-ol’-boy-next-door routine, which he admits
was never much of a stretch for him. The “You
might be a redneck" jokes that put him on the map
came out ot playing gigs in big, non-Southern cities
where dub owners would often tell him, “Faxwor
thy, you’re just an ol’ redneck from Georgia."
On one such occasion, Foxworthy looked out
side a window of the comedy club and saw a bowl
ing alley next door—with a valet-parking stand. He
laughs. “I said, ‘You don’t think you have rednecks
here? Look out the window!’”
So he decided to jot down 10 ways to tell if
you're a redneck. That list blossomed into one of the
most durable routines—and career tracks—in the
business of professional comedy.
“That little yellow piece of paper,” he says with a
smile, “is now framed in our kitchen."
Melonee Hurt McKinney is a writer in Franklin. Tam.
Rate This Story
How did you like this story? Log on
to www.americanprofile.com/rate
Enjoy Jeff Foxworthy at
his rib ticklin’ funniest m I
with this special 3-CD ’ f
set of Crank It Up,
You Might Be A
Redneck 1f... and
Totally Committed.
To order all 3-CD’s for ii jjlrvtL
$34.99 + ONLY $3
delivery, please have your >
credit card ready and
(800) 715-6248 or ■
send check for $37.99 to
Foxworthy Offer - Dept B
AP, P.O. Box 340. Harri
son, AR 72602.
Resklctws of CA. TN. IL, AR and NY add sales tax. NSF (hecks will be automatically
debited far the amount of the check phi* oppliaiblc fees. Oder is limned and oepms fYIAMS.
Phase allow 2-4 weeks far defevery
Page 4
•American Profile